Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target Raised to $330.00 at Royal Bank of Canada

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its target price boosted by equities research analysts at Royal Bank of Canada from $310.00 to $330.00 in a report released on Friday,Benzinga reports. The brokerage presently has an "outperform" rating on the biopharmaceutical company's stock. Royal Bank of Canada's price objective would indicate a potential upside of 17.45% from the stock's previous close.

Other analysts also recently issued reports about the company. Sanford C. Bernstein cut their target price on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an "outperform" rating on the stock in a research note on Tuesday, January 7th. JPMorgan Chase & Co. increased their price objective on Alnylam Pharmaceuticals from $272.00 to $280.00 and gave the company a "neutral" rating in a research report on Tuesday, March 11th. Chardan Capital reiterated a "buy" rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday. Scotiabank upped their target price on shares of Alnylam Pharmaceuticals from $300.00 to $338.00 and gave the company a "sector outperform" rating in a research note on Friday. Finally, HC Wainwright lifted their price target on shares of Alnylam Pharmaceuticals from $400.00 to $500.00 and gave the stock a "buy" rating in a research note on Monday, February 24th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $312.30.

Remove Ads

Alnylam Pharmaceuticals Stock Down 3.4 %

Alnylam Pharmaceuticals stock traded down $9.74 during mid-day trading on Friday, hitting $280.96. The company had a trading volume of 1,065,379 shares, compared to its average volume of 806,039. Alnylam Pharmaceuticals has a 12 month low of $141.98 and a 12 month high of $304.39. The company has a market capitalization of $36.37 billion, a PE ratio of -129.47 and a beta of 0.39. The stock's 50 day moving average price is $258.62 and its two-hundred day moving average price is $260.26. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CEO Yvonne Greenstreet sold 1,213 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the transaction, the chief executive officer now owns 81,526 shares of the company's stock, valued at approximately $20,802,989.42. This represents a 1.47 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CMO Pushkal Garg sold 52,592 shares of the firm's stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total value of $14,988,720.00. Following the sale, the chief marketing officer now directly owns 11,989 shares in the company, valued at approximately $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 71,234 shares of company stock worth $19,958,097. 1.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. OneDigital Investment Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals during the third quarter valued at approximately $281,000. Natixis Advisors LLC purchased a new position in Alnylam Pharmaceuticals during the third quarter valued at $2,751,000. Mutual of America Capital Management LLC grew its stake in Alnylam Pharmaceuticals by 26.7% during the third quarter. Mutual of America Capital Management LLC now owns 1,924 shares of the biopharmaceutical company's stock valued at $529,000 after acquiring an additional 405 shares in the last quarter. Pathstone Holdings LLC increased its holdings in Alnylam Pharmaceuticals by 11.2% in the 3rd quarter. Pathstone Holdings LLC now owns 6,249 shares of the biopharmaceutical company's stock valued at $1,719,000 after acquiring an additional 629 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. Holding AG purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter worth $902,000. 92.97% of the stock is owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.